# Protagonist Therapeutics, Inc: financial statements, quarterly

PTGX · Nasdaq · CIK 1377121 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/ptgx.md) · [Financials](/companies/ptgx/financials.md) · [Filings](/companies/ptgx/filings.md) · [Insiders](/companies/ptgx/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/ptgx/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.0](/filings/0001558370-24-014888.md) | [60.0 d](/filings/0001104659-26-019696.md) | [255](/filings/0001558370-25-006530.md) | [4.2](/filings/0001558370-25-010534.md) | [4.7](/filings/0001104659-25-107816.md) | [171 d](/filings/0001104659-26-019696.md) | [28.3](/filings/0001104659-26-055661.md) | [5.5](/filings/0001104659-26-091123.md) | [4.7](/filings/0001104659-25-107816.md) | [7.4 d](/filings/0001104659-26-019696.md) | [56.4](/filings/0001104659-26-055661.md) | [213](/filings/0001104659-26-091123.md) |
| Research and development | $m | [30.7](/filings/0001558370-24-014888.md) | [28.9 d](/filings/0001104659-26-019696.md) | [33.7](/filings/0001558370-25-006530.md) | [33.5](/filings/0001558370-25-010534.md) | [36.0](/filings/0001104659-25-107816.md) | [34.9 d](/filings/0001104659-26-019696.md) | [35.9](/filings/0001104659-26-055661.md) | [37.0](/filings/0001104659-26-091123.md) | [40.0](/filings/0001104659-25-107816.md) | [46.4 d](/filings/0001104659-26-019696.md) | [46.7](/filings/0001104659-26-055661.md) | [42.1](/filings/0001104659-26-091123.md) |
| Operating income | $m | [(38.3)](/filings/0001558370-24-014888.md) | [23.0 d](/filings/0001104659-26-019696.md) | [206](/filings/0001558370-25-006530.md) | [(38.8)](/filings/0001558370-25-010534.md) | [(41.5)](/filings/0001104659-25-107816.md) | [127 d](/filings/0001104659-26-019696.md) | [(19.3)](/filings/0001104659-26-055661.md) | [(42.0)](/filings/0001104659-26-091123.md) | [(46.4)](/filings/0001104659-25-107816.md) | [(50.4) d](/filings/0001104659-26-019696.md) | [(3.6)](/filings/0001104659-26-055661.md) | [159](/filings/0001104659-26-091123.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [0.0](/filings/0001558370-24-014888.md) | [0.0 d](/filings/0001558370-24-001850.md) | [3.3](/filings/0001558370-25-006530.md) | [(0.7)](/filings/0001558370-25-010534.md) | [(0.4)](/filings/0001104659-25-107816.md) | [2.0 d](/filings/0001104659-26-019696.md) | [0.0](/filings/0001104659-26-055661.md) | [0.2](/filings/0001104659-26-091123.md) | [0.0](/filings/0001104659-25-107816.md) | [0.7 d](/filings/0001104659-26-019696.md) | [(1.5)](/filings/0001104659-26-055661.md) | [2.3](/filings/0001104659-26-091123.md) |
| Net income | $m | [(34.1)](/filings/0001558370-24-014888.md) | [27.3 d](/filings/0001104659-26-019696.md) | [207](/filings/0001558370-25-006530.md) | [(30.6)](/filings/0001558370-25-010534.md) | [(33.2)](/filings/0001104659-25-107816.md) | [132 d](/filings/0001104659-26-019696.md) | [(11.7)](/filings/0001104659-26-055661.md) | [(34.8)](/filings/0001104659-26-091123.md) | [(39.3)](/filings/0001104659-25-107816.md) | [(44.4) d](/filings/0001104659-26-019696.md) | [3.8](/filings/0001104659-26-055661.md) | [163](/filings/0001104659-26-091123.md) |
| Diluted EPS | $ per share | [(0.58)](/filings/0001558370-24-014888.md) | not reported | [3.26](/filings/0001558370-25-006530.md) | [(0.50)](/filings/0001558370-25-010534.md) | [(0.54)](/filings/0001104659-25-107816.md) | not reported | [(0.19)](/filings/0001104659-26-055661.md) | [(0.55)](/filings/0001104659-26-091123.md) | [(0.62)](/filings/0001104659-25-107816.md) | not reported | [0.05](/filings/0001104659-26-055661.md) | [2.29](/filings/0001104659-26-091123.md) |
| Basic EPS | $ per share | [(0.58)](/filings/0001558370-24-014888.md) | not reported | [3.41](/filings/0001558370-25-006530.md) | [(0.50)](/filings/0001558370-25-010534.md) | [(0.54)](/filings/0001104659-25-107816.md) | not reported | [(0.19)](/filings/0001104659-26-055661.md) | [(0.55)](/filings/0001104659-26-091123.md) | [(0.62)](/filings/0001104659-25-107816.md) | not reported | [0.06](/filings/0001104659-26-055661.md) | [2.47](/filings/0001104659-26-091123.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax, us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [231](/filings/0001558370-24-014888.md) | [187](/filings/0001104659-26-019696.md) | [173](/filings/0001558370-25-006530.md) | [356](/filings/0001558370-25-010534.md) | [131](/filings/0001104659-25-107816.md) | [97.2](/filings/0001104659-26-019696.md) | [140](/filings/0001104659-26-055661.md) | [169](/filings/0001104659-26-091123.md) | [114](/filings/0001104659-25-107816.md) | [128](/filings/0001104659-26-091123.md) | [194](/filings/0001104659-26-055661.md) | [420](/filings/0001104659-26-091123.md) |
| Current assets | $m | [325](/filings/0001558370-23-017460.md) | [356](/filings/0001558370-25-001317.md) | [628](/filings/0001558370-24-007081.md) | [571](/filings/0001558370-24-011095.md) | [477](/filings/0001558370-24-014888.md) | [592](/filings/0001104659-26-019696.md) | [606](/filings/0001558370-25-006530.md) | [603](/filings/0001558370-25-010534.md) | [586](/filings/0001104659-25-107816.md) | [578](/filings/0001104659-26-091123.md) | [613](/filings/0001104659-26-055661.md) | [807](/filings/0001104659-26-091123.md) |
| Total assets | $m | [330](/filings/0001558370-23-017460.md) | [358](/filings/0001558370-25-001317.md) | [629](/filings/0001558370-24-007081.md) | [615](/filings/0001558370-24-011095.md) | [604](/filings/0001558370-24-014888.md) | [745](/filings/0001104659-26-019696.md) | [742](/filings/0001558370-25-006530.md) | [718](/filings/0001558370-25-010534.md) | [702](/filings/0001104659-25-107816.md) | [668](/filings/0001104659-26-091123.md) | [697](/filings/0001104659-26-055661.md) | [886](/filings/0001104659-26-091123.md) |
| Current liabilities | $m | [27.9](/filings/0001558370-23-017460.md) | [21.3](/filings/0001558370-25-001317.md) | [39.9](/filings/0001558370-24-007081.md) | [41.6](/filings/0001558370-24-011095.md) | [44.6](/filings/0001558370-24-014888.md) | [47.4](/filings/0001104659-26-019696.md) | [35.1](/filings/0001558370-25-006530.md) | [35.5](/filings/0001558370-25-010534.md) | [44.9](/filings/0001104659-25-107816.md) | [45.4](/filings/0001104659-26-091123.md) | [34.5](/filings/0001104659-26-055661.md) | [37.2](/filings/0001104659-26-091123.md) |
| Total liabilities | $m | [27.9](/filings/0001558370-23-017460.md) | [21.3](/filings/0001558370-25-001317.md) | [68.8](/filings/0001558370-24-007081.md) | [73.3](/filings/0001558370-24-011095.md) | [71.9](/filings/0001558370-24-014888.md) | [69.4](/filings/0001104659-26-019696.md) | [53.1](/filings/0001558370-25-006530.md) | [50.0](/filings/0001558370-25-010534.md) | [56.3](/filings/0001104659-25-107816.md) | [53.5](/filings/0001104659-26-091123.md) | [42.0](/filings/0001104659-26-055661.md) | [44.0](/filings/0001104659-26-091123.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [302](/filings/0001558370-24-014888.md) | [337](/filings/0001104659-26-019696.md) | [560](/filings/0001558370-25-010534.md) | [541](/filings/0001104659-25-107816.md) | [532](/filings/0001104659-25-107816.md) | [675](/filings/0001104659-26-091123.md) | [689](/filings/0001104659-26-091123.md) | [668](/filings/0001104659-26-091123.md) | [645](/filings/0001104659-25-107816.md) | [615](/filings/0001104659-26-091123.md) | [655](/filings/0001104659-26-091123.md) | [842](/filings/0001104659-26-091123.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(26.6) d](/filings/0001558370-24-014888.md) | [17.0 d](/filings/0001104659-26-019696.md) | [(27.4)](/filings/0001558370-25-006530.md) | [269 d](/filings/0001558370-25-010534.md) | [(27.9) d](/filings/0001104659-25-107816.md) | [(29.2) d](/filings/0001104659-26-019696.md) | [125](/filings/0001104659-26-055661.md) | [(28.8) d](/filings/0001104659-26-091123.md) | [(1.9) d](/filings/0001104659-25-107816.md) | [(37.0) d](/filings/0001104659-26-019696.md) | [(48.9)](/filings/0001104659-26-055661.md) | [219 d](/filings/0001104659-26-091123.md) |
| Capital expenditure | $m | [0.4 d](/filings/0001558370-24-014888.md) | [0.0 d](/filings/0001104659-26-019696.md) | [0.2](/filings/0001558370-25-006530.md) | [0.0 d](/filings/0001558370-25-010534.md) | [0.8 d](/filings/0001104659-25-107816.md) | [0.3 d](/filings/0001104659-26-019696.md) | [0.5](/filings/0001104659-26-055661.md) | [0.8 d](/filings/0001104659-26-091123.md) | [0.1 d](/filings/0001104659-25-107816.md) | [0.1 d](/filings/0001104659-26-019696.md) | [0.2](/filings/0001104659-26-055661.md) | [0.2 d](/filings/0001104659-26-091123.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [49.1](/filings/0001558370-23-017460.md) | [50.6](/filings/0001558370-24-007081.md) | [56.8](/filings/0001558370-24-011095.md) | [59.2](/filings/0001558370-24-014888.md) | [63.6](/filings/0001558370-25-006530.md) | [61.3](/filings/0001558370-25-010534.md) | [61.8](/filings/0001104659-25-107816.md) | [63.0](/filings/0001104659-26-055661.md) | [63.5](/filings/0001104659-26-091123.md) | [63.8](/filings/0001104659-25-107816.md) | [70.5](/filings/0001104659-26-055661.md) | [71.0](/filings/0001104659-26-091123.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 64,708,285 at 2026-07-31, from the cover of the [10-Q filed 2026-08-05](/filings/0001104659-26-091123.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:38 ET. No prices; not investment advice.